Journal of the American Heart Association

BRIEF COMMUNICATION

Genetic Evidence for Repurposing of GLP1R (Glucagon-Like Peptide-1 Receptor) Agonists to Prevent Heart Failure

Iyas Daghlas, BS; Ville Karhunen, PhD; Devleena Ray, BSc; Verena Zuber, PhD; Stephen Burgess, PhD; Philip S. Tsao, PhD; Julie A. Lynch, PhD, RN; Kyung Min Lee, PhD; Benjamin F. Voight, PhD; Kyong-Mi Chang, MD; Emma H. Baker, PhD; Scott M. Damrauer, MD; Joanna M. M. Howson, PhD; Marijana Vujkovic, PhD, MSCE; Dipender Gill, BMBCh, PhD

BACKGROUND: This study was designed to investigate the genetic evidence for repurposing of GLP1R (glucagon-like peptide-1 receptor) agonists to prevent heart failure (HF) and whether the potential benefit exceeds the benefit conferred by more general glycemic control.

METHODS AND RESULTS: We applied 2-sample Mendelian randomization of genetically proxied GLP1R agonism on HF as the main outcome and left ventricular ejection fraction as the secondary outcome. The associations were compared with those of general glycemic control on the same outcomes. Genetic associations were obtained from genome-wide association study summary statistics of type 2 diabetes mellitus (228 499 cases and 1 178 783 controls), glycated hemoglobin (n=344 182), HF (47,309 cases and 930 014 controls), and left ventricular ejection fraction (n=16 923). Genetic proxies for GLP1R agonism associated with reduced risk of HF (odds ratio per 1 mmol/mol decrease in glycated hemoglobin 0.75; 95% CI, 0.64–0.87; $P=1.69\times10^{-4}$), and higher left ventricular ejection fraction (SD change in left ventricular ejection fraction per 1 mmol/mol decrease in glycated hemoglobin 0.22%; 95% CI, 0.03–0.42; $P=0.03$). The magnitude of these benefits exceeded those expected from improved glycemic control more generally. The results were similar in sensitivity analyses, and we did not find evidence to suggest that these associations were mediated by reduced coronary artery disease risk.

CONCLUSIONS: This genetic evidence supports the repurposing of GLP1R agonists for preventing HF.

Key Words: diabetes mellitus ■ ejection fraction ■ GLP1R ■ heart failure ■ Mendelian randomization

Patients with type 2 diabetes mellitus are at increased risk of developing heart failure and evidence from randomized controlled trials supports that GLP1R (glucagon-like peptide-1 receptor) agonists reduce this risk.[1,2] The aim of this study was to leverage human genetic data within the Mendelian randomization paradigm to investigate whether effects of GLP1R agonists on heart failure risk and left ventricular ejection fraction (LVEF) exceed those of improved glycemic control more generally.

METHODS

All data used in this work are publicly available and anonymized. All contributing studies received appropriate ethical approval and patient consent.

Methodologic Overview

The Mendelian randomization (MR) approach uses genetic variants as proxies to investigate the causal effect of an exposure on an outcome.[3,4] This method

Correspondence to: Mr Iyas Daghlas, Harvard Medical School, 25 Shattuck St, Boston, MA 02115. E-mail: iyas_daghlas@hms.harvard.edu

Supplementary Material for this article is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.120.020331

For Sources of Funding and Disclosures, see page 5.

© 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

JAHA is available at: www.ahajournals.org/journal/jaha

Downloaded from http://ahajournals.org by on July 19, 2021

leverages the random allocation of genetic variants at conception to reduce any bias due to confounding and reverse causation that can limit causal inference in observational research. MR can be extended to investigate drug effects by leveraging genetic variation in genes (eg, *GLP1R*) encoding proteins corresponding to drug targets.[5]

Genetic Proxies for GLP1R Agonism and Glycemic Control

We identified genetic proxies for the effect of GLP1R agonism as genome-wide significant ($P<5\times10^{-8}$) and uncorrelated ($r^2<0.1$) variants in the *GLP1R* gene (genomic position on build GRCh37/hg19: chromosome 6:39 016 574–39 055 519) that associated with type 2 diabetes mellitus liability in the largest published genome-wide association study meta-analysis (228 499 cases and 1 178 783 controls; 79% European ancestry),[6] with directionally concordant and nominally significant ($P<0.05$) associations with glycated hemoglobin in the UK Biobank (n=344 182).[7] Unless otherwise stated, all downstream analyses were weighted by the variant association with glycated hemoglobin (mmol/mol). These variants were annotated for their sequence effects (eg, intron or missense), and we queried the Genotype-Tissue Expression v8 data set of 54 tissue types to determine whether the variants were associated with gene expression.[8] Variants were annotated as having directionally concordant associations with gene expression if they were associated with lower glycated hemoglobin and greater expression of *GLP1R* (or vice versa).

Genetic proxies for glycemic control more generally were identified through the same associations but considering genetic variants throughout the genome that were not located within 1megabase of *GLP1R*. Given the larger number of variants identified from throughout the genome, we used a stricter clumping threshold of $r^2<0.001$ to minimize bias due to linkage disequilibrium.

Heart Failure and Left Ventricular Ejection Fraction Genetic Association Estimates

Heart failure was the primary outcome for our analysis. We obtained genetic association estimates from the Heart Failure Molecular Epidemiology for Therapeutic Targets Consortium consisting of 47 309 cases and 930 014 controls of European ancestry.[9] Cases included patients with a clinical diagnosis of heart failure, irrespective of the ejection fraction. We further investigated LVEF as a secondary outcome using genetic association estimates from a study of cardiac magnetic resonance imaging derived LVEF in the UK Biobank (n=16 923, all of European ancestry).[10] LVEF was inverse normal-transformed, and the genetic association estimates are therefore presented in approximate SD units.

Statistical Analysis

For each of the variants used in MR analysis, we harmonized genetic associations with the exposure and outcome by aligning effect alleles, with no exclusion made for palindromic variants. We derived MR estimates considering genetically proxied GLP1R agonism and glycemic control more generally using the random-effects inverse-variance weighted method with intercept fixed at the origin,[3] orientating estimates to reduction in glycated hemoglobin (ie, the direction of drug effect). All MR analyses were performed using the TwoSampleMR package in R.[3] To assess for a GLP1R agonism drug class effect that exceeds the anticipated effect of glycemic control more generally, we tested for a significant difference between the respective MR estimates. The point estimate for this difference was obtained by taking the difference between the MR beta coefficients for the GLP1R and glycemic control estimates, and the SE for the difference was derived using the propagation of error method:

$$SE\left(\beta_{GLP1R}-\beta_{GLYCEMIA}\right)=\sqrt{SE\left(\beta_{GLP1R}\right)^2+SE\left(\beta_{GLYCEMIA}\right)^2},$$

where β_{GLP1R} and $\beta_{GLYCEMIA}$ are the MR estimates for the associations of genetically proxied GLP1R agonism and glycemic control with the outcomes.

Analyses investigating LVEF as a secondary outcome were considered exploratory, and so the *P* values were not corrected for multiple comparisons. All hypothesis tests were 2 sided.

Sensitivity Analyses

In sensitivity analyses considering GLP1R agonism we restricted the genetic proxies to coding variation in *GLP1R*, as these variants more plausibly relate to *GLP1R* function. Corresponding MR estimates that used a single proxy variant were derived using the Wald ratio with first-order SEs. We also performed analyses excluding any coding variants to ensure that they were not solely driving the MR estimates. To determine whether results were sensitive to our choice to weight the variants by their associations with glycated hemoglobin, we also performed analyses weighted by the log-odds of type 2 diabetes mellitus liability. MR estimates may be biased by horizontal pleiotropy if the genetic variants proxying GLP1R agonism influence heart failure risk or LVEF through a pathway independent of GLP1R agonism. We first tested for any such bias by calculating the Cochran Q test *P* value to assess for overdispersion in the MR estimates provided by each variant in the GLP1R agonism instrument. We then performed analyses using the weighted median

Downloaded from http://ahajournals.org by on July 19, 2021

method, which provides consistent MR estimates if more than half of the weight from the genetic proxies comes from valid instrumental variables.[11]

To determine whether protective effects of GLP1R agonism on heart failure may be mediated by reduced coronary artery disease risk, we performed MR analyses investigating the effect of GLP1R agonism on coronary artery disease risk. We obtained genetic association estimates from a meta-analysis of data from the CARDIOGRAMplusC4D Consortium and UK Biobank consisting of 122 733 cases and 424 528 controls of European ancestry.[12]

RESULTS

Identification of Genetic Proxies for GLP1R Agonism and Glycemic Control More Generally

Three independent variants in *GLP1R* were identified as genetic proxies for GLP1R agonism, including 1 missense variant (rs10305420) and 2 intronic variants (rs2268647 and rs75151020; Tables S1–S2). Two of these variants were significantly associated with expression of *GLP1R* across several human tissues, and both variants had directionally concordant associations with *GLP1R* expression in pancreatic tissue (Table S3). A directionally discordant association with *GLP1R* expression in left ventricular and left atrial appendage myocardial tissue was identified for the intronic variant rs2268647 (Table S3). There were 350 variants available for use as proxies for glycemic control more generally in the heart failure data set (Table S4) and 334 variants available in the LVEF data set (Table S5).

Mendelian Randomization Analyses

Genetically proxied GLP1R agonism associated with a reduced risk of heart failure (odds ratio [OR] per 1 mmol/mol decrease in glycated hemoglobin, 0.75; 95% CI, 0.64–0.87; P=1.69×10^{-4}). This estimate was similar in MR analysis only using the missense variant rs10305420 (OR, 0.62; 95% CI, 0.45–0.85; P=2.59×10^{-3}). Analyses excluding this variant provided similar evidence of effect, suggesting that this variant did not solely drive the estimates (OR, 0.79; 95% CI, 0.67–0.92; P=3.33×10^{-3}). Consistent with previous reports,[9] a genetically proxied improvement in overall glycemic control associated with reduced risk of heart failure (OR, 0.96; 95% CI, 0.94–0.97; P=7.75×10^{-11}). This estimate was smaller in magnitude than the estimate obtained for genetically proxied GLP1R agonism ($P_{difference}$=1.58×10^{-3}; Figure).

Genetically proxied GLP1R agonism associated with a higher LVEF (SD change in LVEF, 0.22; 95% CI, 0.03–0.42; P=0.03). There was no evidence of an association between genetically proxied glycemic control more generally and LVEF (SD change in LVEF, 0.00; 95% CI, −0.01 to 0.02; P=0.67). This estimate was smaller in magnitude than that obtained for genetically proxied GLP1R agonism ($P_{difference}$=0.03). Corresponding scatter plots for all analyses are provided in Figures S1–S5.



Figure. Forest plot depicting Mendelian randomization estimates for the association of genetically proxied GLP1R (glucagon-like peptide receptor) agonism and glycemic control more generally with (A) risk of heart failure (HF; 47 309 cases/930 014 controls) and (B) left ventricular ejection fraction (LVEF; n=16 923).
Estimates reflect the effect of a reduction in glycated hemoglobin on each of the respective outcomes (so as to orient estimates to GLP1R agonist drug effects). Squares correspond to point estimates, and the surrounding lines correspond to 95% CIs. diff indicates difference; and OR, odds ratio.

Downloaded from http://ahajournals.org by on July 19, 2021

Sensitivity Analyses

Analyses weighting the genetic proxies for GLP1R agonism (OR per log-odds increase in type 2 diabetes mellitus liability, 0.48; 95% CI, 0.34–0.67; P=2.87×10^{-5}) and overall glycemic control (OR, 0.90; 95% CI, 0.87–0.93; P=1.81×10^{-12}) by type 2 diabetes mellitus liability showed similar evidence for a reduction in heart failure risk. There was no significant heterogeneity in the MR estimates generated by the different variants when considering either heart failure or LVEF as outcomes (Figures S1–S3). Results from analyses using the weighted median method showed significant protective associations of genetically proxied GLP1R agonism (OR, 0.77; 95% CI, 0.62–0.96; P=0.02) and improved glycemic control (OR, 0.98; 95% CI, 0.96–1.00; P=0.04) with heart failure risk, and directionally concordant but nonsignificant associations of genetically proxied GLP1R agonism with LVEF (SD change in LVEF, 0.18; 95% CI, −0.07 to 0.42; P=0.16; Table S6). We found no evidence for an association of genetically proxied GLP1R agonism with coronary artery disease risk (OR per 1 mmol/mol decrease in glycated hemoglobin, 1.02; 95% CI, 0.89–1.16; P=0.80).

DISCUSSION

In this MR study, we used human genetic data to identify proxies for GLP1R agonism and found evidence for their protective effect on risk of heart failure. In secondary analyses, we found associations of genetically proxied GLP1R agonism with increased LVEF. The magnitude of these estimates exceeded those generated using genetic proxies for glycemic control more generally, supporting a role for GLP1R signaling in preventing heart failure beyond an effect on glycemic control alone.[13] We did not find evidence of heterogeneity in the MR estimates generated by the genetic proxies for GLP1R agonism when considering either heart failure or LVEF as outcomes, and results were similar in sensitivity analyses using the weighted median method, with the null effect of GLP1R agonism on LVEF potentially attributable to low statistical power. The null effect of genetically proxied GLP1R agonism on coronary artery disease risk suggests that a reduced risk of heart failure is not attributable to chronic ischemic heart disease.

Our findings are consistent with meta-analyses of randomized controlled trials identifying a protective effect of GLP1R agonists on hospital admission with heart failure[1,2] and go further to provide genetic evidence supporting a drug effect on LVEF. Further clinical research is needed to determine contexts where GLP1R agonists may be repurposed for reducing risk of heart failure, particularly given the established effects of sodium glucose cotransporter 2 inhibitors for reducing progression of heart failure in patients with and without type 2 diabetes mellitus.[14]

A similar genetic approach was previously used to support a protective effect of GLP1R agonism on coronary artery disease risk[15]; however, our analyses did not replicate this finding. The previous investigation used a low-frequency missense variant, rs10305492, which is not in strong linkage disequilibrium with any of the variants included in our investigation (all pairwise r^2<0.16). We did not select this variant for inclusion in our analysis as its association with type 2 diabetes mellitus achieved only a nominal level of statistical significance (P=0.001), and not the more stringent genome-wide level of statistical significance achieved by the variants in our investigation. In contrast, meta-analyses of clinical trials have supported a nominally significant (P=0.043 before adjustment for multiple comparisons) beneficial effect of GLP1R agonism on myocardial infarction.[1] Given the small magnitude of this reported effect (hazard ratio, 0.91; 95% CI, 0.84–1.00[1]) and the span of the CIs from our MR estimates (95% CI, 0.89–1.16), it is plausible that the null MR estimate for coronary artery disease is attributable to low statistical power.

The key strength of our work is the use of randomly allocated genetic proxies to study the effects of GLP1R agonism. The genetic proxies used in these analyses were further validated by their associations with glycated hemoglobin, which reduces risk of bias due to winner's curse and permits the contextualization of the MR estimates on the glycated hemoglobin scale. The genetic associations with LVEF were adjusted for body mass index, which allowed standardization for body size. A study limitation is the absence of available large-scale genetic summary data for heart failure subtypes. Although we used a missense variant in *GLP1R* (rs10305420) and gene expression data to strengthen the validity of our findings, further experimental work is necessary to determine the mechanism by which these variants influence *GLP1R* expression or function. In particular, the directionally concordant association of the rs2268647 intronic variant on gene expression in the pancreas, but discordant effect on *GLP1R* expression in myocardial tissue warrants further exploration. The MR estimates reflect the consequence of a lifelong genetic perturbation of GLP1R signaling and cannot be extrapolated to predict the magnitude of effect from shorter, discrete pharmacological interventions. The limited number of genetic variants available to instrument GLP1R agonism precluded more extensive sensitivity analyses for horizontal pleiotropy. In particular, modeling an intercept term (as in the MR-Egger regression approach) can in some scenarios mitigate bias from unbalanced horizontal

Downloaded from http://ahajournals.org by on July 19, 2021

pleiotropy but was not appropriate in our analysis of GLP1R agonism because of the availability of only 3 genetic proxies. We used summary-level genetic associations with heart failure and LVEF and therefore could not perform stratified analyses, such as by sex or diabetes mellitus status. Finally, these genetic data were predominantly gathered from individuals of European ancestry and these results may therefore not generalize to other ethnic groups.

CONCLUSIONS

In conclusion, we identified genetic proxies for the effects of GLP1R agonism, and applied these proxies in MR analyses to generate evidence supporting a protective effect on risk of heart failure. Further investigation of GLP1R agonist repurposing to prevent heart failure in the context of clinical trials is warranted.

ARTICLE INFORMATION

Received November 26, 2020; Revised April 27, 2021; accepted May 3, 2021.

Affiliations

Harvard Medical School, Boston, MA (I.D.); Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK (V.K., D.R., V.Z., D.G.); Medical Research Council Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, UK (V.Z., S.B.); Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK (S.B.); VA Palo Alto Health Care System, Palo Alto, CA (P.S.T.); Department of Medicine, Stanford University School of Medicine, Stanford, CA (P.S.T.); Department of Veterans Affairs, VA Informatics and Computing Infrastructure, Salt Lake City Health Care System, Salt Lake City, UT (J.A.L., K.M.L.); Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT (J.A.L.); Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA (B.F.V., K.-M.C., S.M.D., M.V.); Department of Genetics (B.F.V.), Department of Systems Pharmacology and Translational Therapeutics (B.F.V.), Institute of Translational Medicine and Therapeutics (B.F.V.), Department of Medicine (K.-M.C., M.V.), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA (S.M.D.); Clinical Pharmacology and Therapeutics Section, Institute of Medical and Biomedical Education and Institute for Infection and Immunity, St George's, University of London, London, UK (E.H.B., D.G.); Clinical Pharmacology Group, Pharmacy and Medicines Directorate, St George's University Hospitals NHS Foundation Trust, London, UK (E.H.B., D.G.); Novo Nordisk Research Centre Oxford, Oxford, UK (J.M.M.H., D.G.).

Acknowledgments

Author Contributions: D.G. and I.D. designed the study. I.D., D.G., V.K., and D.R. performed statistical analyses and drafted the article. All authors interpreted results, edited the article for intellectual content, and take responsibility for the integrity of the study.

Sources of Funding

D.G. was supported by the Wellcome Trust 4i Programme (203928/Z/16/Z) and British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College, and a National Institute for Health Research Clinical Lectureship (CL-2020-16-001) at St. George's, University of London. S.B. is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (204623/Z/16/Z). B.F.V. was supported by the National Institutes of Health (DK101478) and a Linda Pechenik Montague Investigator award. P.S.T. and K.-M.C. are supported by the VA Cooperative Studies Program with funding from the VA award I01-BX003362. S.M.D. was supported by the Department of Veterans Affairs Office of Research and Development (IK2-CX001780). Million Veterans Program research data are funded by Office of Research and Development, Veterans Health Administration and supported by award no. MVP000. MVP-based articles do not represent the views of the VA, the US Food and Drug Administration, or the US Government. This work was supported by funding from the National Institute for Health Research (NIHR; Cambridge Biomedical Research Centre at the Cambridge University Hospitals National Health Service [NHS] Foundation Trust). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funding sources had no role in the design, acquisition of data, analysis, interpretation or write up of this study.

Disclosures

D.G. is employed part time by Novo Nordisk and has received consultancy fees from Policy Wisdom. J.M.M.H. is an employee of Novo Nordisk. S.M.D. has received grants from the U.S. Department of Veterans Affairs, Calico Labs, and Renalytix AI plc outside the submitted work. The remaining authors have no disclosures to report.

Supplementary Material

Tables S1–S6
Figures S1–S5

REFERENCES

1. Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Køber L, Petrie MC, McMurray JJV. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet Diabetes Endocrinol*. 2019;7:776–785. DOI: 10.1016/S2213-8587(19)30249-9.
2. Honigberg MC, Chang L-S, McGuire DK, Plutzky J, Aroda VR, Vaduganathan M. Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease. *JAMA Cardiol*. 2020;5:1182. DOI: 10.1001/jamacardio.2020.1966.
3. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon R, et al. The MR-Base platform supports systematic causal inference across the human phenome. *Elife*. 2018;7:e34408. DOI: 10.7554/eLife.34408.
4. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol*. 2003;32:1–22. DOI: 10.1093/ije/dyg070.
5. Gill D, Georgakis MK, Koskeridis F, Jiang L, Feng Q, Wei W-Q, Theodoratou E, Elliott P, Denny JC, Malik R, et al. Use of genetic variants related to antihypertensive drugs to inform on efficacy and side effects. *Circulation*. 2019;140:270–279. DOI: 10.1161/CIRCULATIONAHA.118.038814.
6. Vujkovic M, Keaton JM, Lynch JA, Miller DR, Zhou J, Tcheandjieu C, Huffman JE, Assimes TL, Lorenz K, Zhu X, et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nat Genet*. 2020;52:680–691. DOI: 10.1038/s41588-020-0637-y.
7. NealeLab. Rapid GWAS of thousands of phenotypes for 337,000 samples in the UK Biobank. 2020 [cited 2020 Jun 16]. Available from: http://www.nealelab.is/uk-biobank.
8. GTEX consortium. Genetic effects on gene expression across human tissues. *Nature*. 2017;550:204–213. DOI: 10.1038/nature24277.
9. Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, Hedman ÅK, Wilk JB, Morley MP, Chaffin MD, et al. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. *Nat Commun*. 2020;11:163. DOI: 10.1038/s41467-019-13690-5.
10. Aung N, Vargas JD, Yang C, Cabrera CP, Warren HR, Fung K, Tzanis E, Barnes MR, Rotter JI, Taylor KD, et al. Genome-wide analysis of left ventricular image-derived phenotypes identifies fourteen loci associated with cardiac morphogenesis and heart failure development. *Circulation*. 2019;140:1318–1330. DOI: 10.1161/CIRCULATIONAHA.119.041161.
11. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. *Genet Epidemiol*. 2016;40:304–314. DOI: 10.1002/gepi.21965.
12. van der Harst P, Verweij N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary

Downloaded from http://ahajournals.org by on July 19, 2021

artery disease. *Circ Res*. 2018;122:433–443. DOI: 10.1161/CIRCRESAHA.117.312086.
13. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. *Cell Metab*. 2016;24:15–30. DOI: 10.1016/j.cmet.2016.06.009.
14. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med*. 2019;381:1995–2008. DOI: 10.1056/NEJMoa1911303.
15. Scott RA, Freitag DF, Li L, Chu AY, Surendran P, Young R, Grarup N, Stancáková A, Chen Y, Varga TV, et al. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. *Sci Transl Med*. 2016;8:341ra76. DOI: 10.1126/scitranslmed.aad3744.

Downloaded from http://ahajournals.org by on July 19, 2021

SUPPLEMENTAL MATERIAL

Downloaded from http://ahajournals.org by on July 19, 2021

Table S1. Genetic proxies for GLP1R agonism, and estimates for their association with glycated hemoglobin, type 2 diabetes, heart failure, and left ventricular ejection fraction.

						Glycated hemoglobin			Type 2 diabetes			Heart failure			Left ventricular ejection fraction		
SNP	**Chr**	**Position**	**EA**	**OA**	**EAF**	**Beta**	**SE**	**P**	**Beta**	**SE**	**P**	**Beta**	**SE**	**P**	**Beta**	**SE**	**P**
rs10305420*	6	39016636	T	C	0.39	-0.051	0.016	1.30×10^{-3}	-0.032	0.004	5.11×10^{-14}	-0.024	0.008	2.63×10^{-3}	-0.009	0.011	4.1×10^{-1}
rs75151020	6	39031592	C	A	0.09	0.119	0.026	7.08×10^{-6}	0.041	0.007	1.37×10^{-9}	-0.022	0.013	1.04×10^{-1}	0.040	0.019	3.4×10^{-2}
rs2268647	6	39043178	T	C	0.52	0.066	0.015	1.51×10^{-5}	0.021	0.004	4.95×10^{-8}	0.019	0.007	1.12×10^{-2}	0.008	0.011	4.4×10^{-1}

Chr: chromosome; EA: effect allele; EAF: effect allele frequency; OA: other allele; SE: standard error; SNP: single nucleotide polymorphism. *: missense variant

Downloaded from http://ahajournals.org by on July 19, 2021

Table S2. Linkage disequilibrium r^2 values for variants used as proxies for GLP1R agonism.

rsID	rs10305420	rs75151020	rs2268647
rs10305420	1.00	0.01	0.00
rs75151020	0.01	1.00	0.07
rs2268647	0.00	0.06	1.00

r^2 values were obtained using linkage disequlibrium data from the European subsample of the 1000 Genomes project (https://ldlink.nci.nih.gov/?tab=ldmatrix).

Downloaded from http://ahajournals.org by on July 19, 2021

Table S3. Genetic proxies for GLP1R agonism, and estimates for their association with gene expression in the GTEx v8 database.

Gene Symbol	SNP	P-Value	NES	Directional concordance with glycated hemoglobin	Tissue
GLP1R	rs10305420	2.10E-09	0.23	Yes	Nerve - Tibial
GLP1R	rs10305420	3.80E-06	0.26	Yes	Adipose - Visceral (Omentum)
GLP1R	rs10305420	4.10E-06	0.25	Yes	Thyroid
GLP1R	rs10305420	2.30E-05	0.24	Yes	Pancreas
GLP1R	rs2268647	1.00E-09	0.31	No	Heart - Left Ventricle
GLP1R	rs2268647	2.10E-07	0.23	No	Heart - Atrial Appendage
GLP1R	rs2268647	3.40E-07	-0.33	Yes	Stomach
GLP1R	rs2268647	2.10E-06	-0.27	Yes	Pancreas
GLP1R	rs2268647	1.60E-05	-0.23	Yes	Thyroid
ANKRD18EP	rs2268647	2.20E-05	-0.12	Yes	Skin - Sun Exposed (Lower leg)

rs75151020 did not significantly influence gene expression in any of the tissues in the GTEx database. Variants were annotated as directionally concordant if they were associated with lower glycated hemoglobin and higher expression of *GLP1R* (or vice versa). NES: normalized effect size; SNP: single nucleotide polymorphism.

Downloaded from http://ahajournals.org by on July 19, 2021

Table S4. Genetic proxies for glycemic control by any mechanism, and estimates for their association with glycated hemoglobin (for the outcome of heart failure).

SNP	Chromosome	Position	Effect allele	Other allele	EAF	Beta	SE
rs2482506	10	104563743	G	C	0.25	-0.053	0.018
rs79364741	10	114666651	T	C	0.01	-0.164	0.073
rs11196174	10	114734096	G	A	0.29	0.252	0.017
rs149692182	10	114752674	T	C	0.02	0.309	0.053
rs35676242	10	114757314	A	C	0.05	0.230	0.036
rs11257655	10	12307894	T	C	0.21	0.219	0.019
rs946859	10	13565429	A	G	0.47	-0.075	0.015
rs3122231	10	44027356	C	T	0.65	0.050	0.016
rs113899647	10	64850074	T	C	0.03	-0.189	0.044
rs949693	10	70354574	A	G	0.61	-0.050	0.016
rs11592899	10	71333783	A	G	0.34	-0.055	0.016
rs2812535	10	71456857	A	G	0.62	0.069	0.016
rs697239	10	80947438	C	T	0.46	-0.105	0.015
rs11201992	10	88117318	A	C	0.46	-0.038	0.015
rs1111875	10	94462882	T	C	0.41	-0.181	0.016
rs66536955	10	94737667	C	T	0.26	0.044	0.017
rs34041345	10	99174580	G	T	0.26	0.060	0.018
rs529623	11	117693255	C	T	0.52	-0.059	0.015
rs10893830	11	128044159	T	C	0.13	-0.058	0.023
rs10750397	11	128234144	G	A	0.72	-0.040	0.017
rs67232546	11	128398938	T	C	0.21	0.067	0.019
rs117316450	11	14518419	G	C	0.02	0.316	0.054
rs757110	11	17418477	A	C	0.64	-0.112	0.016
rs11042987	11	2201059	A	C	0.58	-0.034	0.016
rs10831668	11	2288412	T	C	0.02	0.234	0.060
rs231362	11	2691471	G	A	0.52	0.120	0.015
rs10767659	11	27686196	T	G	0.67	-0.041	0.016

Downloaded from http://ahajournals.org by on July 19, 2021

rs60808706	11	2857233	A	G	0.05	-0.227	0.035
rs2289488	11	2892955	C	G	0.40	0.040	0.016
rs62618693	11	32956492	T	C	0.05	-0.144	0.037
rs523472	11	35031668	A	G	0.72	-0.056	0.017
rs3816605	11	47857253	C	T	0.45	-0.080	0.015
rs7483027	11	58128015	C	T	0.38	-0.061	0.016
rs174541	11	61565908	C	T	0.36	-0.098	0.016
rs1143756	11	65299595	G	A	0.29	0.100	0.017
rs3918296	11	69459036	G	C	0.03	-0.249	0.049
rs11602873	11	72460762	T	A	0.16	-0.187	0.021
rs11236524	11	75464344	C	T	0.09	0.069	0.027
rs4945090	11	76205018	A	T	0.60	0.036	0.016
rs12802861	11	8387806	T	C	0.28	-0.052	0.017
rs10830963	11	92708710	G	C	0.28	0.297	0.017
rs3020069	11	93057087	A	G	0.68	0.093	0.016
rs1426371	12	108629780	A	G	0.26	-0.074	0.018
rs79310463	12	118406696	T	C	0.13	0.104	0.023
rs56348580	12	121432117	C	G	0.31	-0.037	0.017
rs7975763	12	123604053	T	C	0.20	-0.057	0.019
rs11614914	12	133070294	T	C	0.33	0.078	0.016
rs12828318	12	133766122	G	A	0.18	-0.057	0.020
rs10841886	12	21864377	C	T	0.23	-0.082	0.018
rs1480029	12	26356032	A	G	0.46	0.042	0.015
rs3751239	12	27963676	G	C	0.20	-0.160	0.019
rs11063018	12	4288001	C	T	0.17	0.067	0.020
rs74862545	12	4365572	T	C	0.02	-0.279	0.052
rs76895963	12	4384844	G	T	0.02	-1.037	0.059
rs2732469	12	48712932	A	T	0.43	-0.258	0.015
rs61937817	12	57212823	G	T	0.11	0.060	0.024
rs11173646	12	61250814	T	A	0.82	-0.046	0.020
rs2257883	12	66216162	A	G	0.13	0.150	0.023
rs12371967	12	66346714	C	T	0.17	-0.043	0.020

Downloaded from http://ahajournals.org by on July 19, 2021

rs10879261	12	71520761	G	T	0.41	0.068	0.016
rs11108094	12	95928113	A	C	0.07	0.099	0.030
rs6538805	12	97849120	C	T	0.39	-0.076	0.016
rs9587811	13	109946882	A	C	0.41	-0.056	0.016
rs314879	13	23309382	T	C	0.79	-0.069	0.019
rs34584161	13	26776999	G	A	0.24	-0.063	0.018
rs380854	13	33574631	A	G	0.58	-0.058	0.016
rs9316500	13	51094114	G	T	0.29	-0.067	0.017
rs7991679	13	58691107	A	T	0.16	-0.081	0.021
rs1215451	13	80715893	A	G	0.29	-0.131	0.017
rs112324411	14	101258584	T	C	0.07	-0.101	0.032
rs2295388	14	101309759	A	G	0.22	-0.073	0.019
rs4906272	14	103376031	T	C	0.16	0.046	0.021
rs12883788	14	33303540	T	C	0.46	0.060	0.015
rs7147483	14	38804675	C	T	0.25	-0.158	0.018
rs723355	14	47304091	A	G	0.50	-0.034	0.015
rs4902002	14	61229411	A	G	0.71	-0.034	0.017
rs242105	14	69459229	C	A	0.28	0.062	0.017
rs7156625	14	79942647	A	G	0.22	0.037	0.019
rs8010382	14	91963722	G	A	0.41	0.046	0.016
rs8043085	15	38828140	T	G	0.23	0.071	0.018
rs11856877	15	40620560	G	A	0.11	0.071	0.024
rs1473781	15	41818917	A	G	0.35	0.067	0.016
rs149336329	15	52587740	T	G	0.05	-0.272	0.037
rs7163757	15	62391608	T	C	0.43	-0.042	0.015
rs7178762	15	63871292	T	C	0.55	-0.057	0.015
rs9479	15	74328576	G	A	0.49	0.052	0.015
rs8033589	15	75596685	A	G	0.76	0.058	0.018
rs12910361	15	77782335	G	A	0.71	0.161	0.017
rs893617	15	90381278	T	C	0.72	-0.136	0.017
rs2290202	15	91512267	T	G	0.13	0.085	0.023
rs9927842	16	15153717	C	T	0.84	-0.056	0.021

Downloaded from http://ahajournals.org by on July 19, 2021

rs8056890	16	28897452	A	G	0.36	0.105	0.016
rs8054556	16	29958216	A	G	0.47	0.077	0.015
rs55857387	16	300388	C	T	0.20	-0.142	0.019
rs8061528	16	3656482	T	C	0.21	0.092	0.019
rs2024449	16	53494617	C	T	0.44	-0.056	0.015
rs1421085	16	53800954	C	T	0.40	0.154	0.016
rs56125990	16	69742387	G	A	0.15	0.065	0.021
rs4788815	16	71634811	T	A	0.66	0.056	0.016
rs72802365	16	75246035	C	G	0.08	-0.163	0.029
rs2966117	16	81599271	T	G	0.48	0.059	0.015
rs11117364	16	88132199	G	A	0.68	0.066	0.017
rs9937296	16	88554480	C	T	0.86	0.069	0.023
rs66461358	16	89535257	C	T	0.15	0.060	0.021
rs12934854	16	950028	A	G	0.17	0.043	0.020
rs925095	17	17344653	T	C	0.39	-0.075	0.016
rs2297508	17	17715317	G	C	0.65	-0.150	0.016
rs117642733	17	21284910	T	C	0.05	0.107	0.039
rs9913225	17	27570622	A	G	0.58	-0.075	0.016
rs1109442	17	34862220	C	T	0.47	0.071	0.015
rs3110641	17	36047417	G	A	0.78	0.091	0.019
rs11651755	17	36099840	T	C	0.51	-0.124	0.015
rs3786017	17	3830340	C	T	0.11	0.054	0.025
rs8071043	17	3988451	C	T	0.33	0.066	0.016
rs1905339	17	40582296	C	T	0.34	0.097	0.016
rs35895680	17	47060322	A	C	0.33	-0.089	0.016
rs366577	17	4854480	T	C	0.60	-0.051	0.016
rs57767539	17	62203059	A	G	0.07	0.136	0.031
rs11658220	17	65646092	A	G	0.10	0.100	0.025
rs12603589	17	65825248	C	T	0.19	0.103	0.020
rs7224711	17	76772288	T	C	0.53	-0.069	0.015
rs303760	18	21083738	T	C	0.35	0.052	0.016
rs16965062	18	31581247	T	C	0.43	0.034	0.015

Downloaded from http://ahajournals.org by on July 19, 2021

rs7227272	18	36746623	A	G	0.10	-0.062	0.026
rs410150	18	40066006	T	C	0.80	-0.047	0.019
rs17596995	18	53166594	A	G	0.20	-0.049	0.019
rs1517037	18	56878274	T	C	0.19	-0.093	0.020
rs6567160	18	57829135	C	T	0.23	0.097	0.018
rs74625348	18	60846430	C	G	0.23	-0.044	0.019
rs12963820	18	63426213	A	T	0.27	0.034	0.017
rs7240767	18	7070642	C	T	0.39	0.063	0.016
rs6565922	18	74558999	T	C	0.38	0.078	0.016
rs9384	19	13010643	T	G	0.38	-0.107	0.016
rs10404726	19	18834514	T	C	0.47	-0.035	0.015
rs58542926	19	19379549	T	C	0.08	0.139	0.029
rs924150	19	31829903	C	A	0.39	-0.087	0.016
rs4805881	19	33896432	C	A	0.67	-0.077	0.016
rs429358	19	45411941	C	T	0.16	-0.142	0.021
rs8107527	19	46158417	A	G	0.28	0.105	0.017
rs9304665	19	47602577	A	T	0.77	0.103	0.018
rs2115107	19	7968168	A	G	0.38	0.069	0.016
rs116843064	19	8429323	A	G	0.02	-0.150	0.055
rs7554251	1	11317932	C	T	0.73	0.036	0.017
rs1127215	1	117532790	T	C	0.42	-0.065	0.016
rs66464442	1	118171801	A	C	0.32	0.121	0.016
rs1493694	1	120526982	T	C	0.11	0.146	0.025
rs145904381	1	151017991	C	T	0.01	-0.266	0.071
rs2297607	1	154320942	G	A	0.24	0.051	0.018
rs6696888	1	155508882	A	G	0.68	-0.048	0.016
rs7546252	1	172368310	G	A	0.56	-0.092	0.015
rs539515	1	177889025	C	A	0.21	0.049	0.019
rs2816177	1	179248952	G	A	0.41	0.049	0.016
rs41304257	1	201849926	G	A	0.28	-0.042	0.017
rs61817176	1	206621028	C	A	0.52	-0.074	0.015
rs10916780	1	20707153	G	A	0.20	-0.045	0.019

Downloaded from http://ahajournals.org by on July 19, 2021

rs340874	1	214159256	C	T	0.57	0.166	0.015
rs1337101	1	219726100	T	G	0.32	-0.095	0.016
rs348330	1	229672955	A	G	0.63	-0.119	0.016
rs10925635	1	235573486	C	A	0.64	0.046	0.016
rs17261915	1	26756856	C	T	0.25	0.074	0.018
rs3753693	1	29060898	T	C	0.41	-0.066	0.016
rs61779284	1	39855177	A	G	0.21	0.130	0.019
rs79090772	1	51209148	C	T	0.09	-0.219	0.027
rs2269247	1	64107284	T	C	0.18	-0.056	0.020
rs11583755	1	6672729	C	A	0.36	0.107	0.016
rs2613499	1	72751552	G	A	0.19	-0.052	0.019
rs10159026	1	96404462	T	C	0.25	-0.062	0.018
rs6137042	20	2100095	A	G	0.20	-0.050	0.019
rs7274134	20	22428284	T	C	0.25	-0.062	0.018
rs6059662	20	32675727	G	A	0.65	0.037	0.016
rs2038457	20	42239145	G	A	0.81	0.041	0.020
rs12625671	20	42994812	C	T	0.11	0.118	0.025
rs6066138	20	45594711	A	G	0.28	-0.135	0.017
rs6021276	20	50155386	C	T	0.64	-0.074	0.016
rs865034	20	51261615	C	T	0.66	0.040	0.016
rs4810145	20	57396495	C	T	0.52	0.068	0.015
rs6011155	20	62450664	C	T	0.37	-0.074	0.016
rs2240716	22	19969696	T	C	0.30	0.074	0.017
rs56392746	22	30451688	A	G	0.09	-0.138	0.026
rs75307421	22	32203334	A	G	0.02	0.151	0.061
rs138771	22	35705359	G	A	0.81	-0.055	0.020
rs1801645	22	50356850	T	C	0.74	-0.059	0.018
rs34506349	2	100598726	A	G	0.04	-0.099	0.038
rs79950062	2	111940612	C	T	0.13	-0.053	0.023
rs9308614	2	121337196	G	A	0.15	-0.090	0.022
rs6716394	2	146350724	A	G	0.54	-0.045	0.015
rs4668483	2	16231732	G	A	0.68	-0.040	0.016

Downloaded from http://ahajournals.org by on July 19, 2021

rs10184004	2	165508389	T	C	0.41	-0.115	0.016
rs11680058	2	16574669	A	G	0.87	0.104	0.025
rs13406280	2	166610827	T	C	0.49	-0.047	0.015
rs72917531	2	175238176	A	C	0.19	-0.078	0.020
rs36051007	2	179545859	T	C	0.32	-0.035	0.017
rs67383253	2	181570394	C	T	0.37	-0.035	0.016
rs6712905	2	196952010	C	T	0.26	0.048	0.018
rs4482463	2	205375909	A	C	0.92	-0.063	0.029
rs34329895	2	208870017	G	A	0.60	-0.063	0.016
rs2943650	2	227105921	T	C	0.65	0.143	0.016
rs13415288	2	228971884	C	T	0.34	0.059	0.016
rs34339006	2	234271522	T	C	0.39	0.092	0.016
rs1260326	2	27730940	C	T	0.61	0.156	0.016
rs77165542	2	430975	T	C	0.04	-0.155	0.042
rs921069	2	43206922	G	A	0.58	-0.038	0.016
rs76675804	2	43611883	C	T	0.10	-0.311	0.026
rs10193538	2	58981064	T	G	0.61	0.072	0.016
rs243018	2	60586707	G	C	0.45	0.088	0.016
rs114213622	2	65243284	T	G	0.01	-0.303	0.080
rs10188334	2	653874	T	C	0.17	-0.087	0.020
rs12185610	2	65661468	C	A	0.41	-0.063	0.016
rs4671799	2	67622243	G	A	0.68	-0.036	0.016
rs4832290	2	86707504	C	T	0.77	-0.053	0.018
rs17036126	3	12287863	T	C	0.13	0.127	0.023
rs11708067	3	123065778	G	A	0.25	-0.262	0.018
rs17036160	3	12329783	T	C	0.12	-0.088	0.024
rs9873519	3	124921457	T	C	0.53	0.097	0.015
rs1224997	3	131631201	T	C	0.28	0.072	0.017
rs667920	3	136069472	T	G	0.77	0.038	0.018
rs9289556	3	138033181	T	C	0.73	-0.077	0.017
rs56243018	3	141101839	C	A	0.05	-0.214	0.036
rs28502438	3	149220109	C	T	0.43	-0.051	0.016

Downloaded from http://ahajournals.org by on July 19, 2021

rs7633673	3	152084243	A	G	0.41	-0.086	0.016
rs11706810	3	160159921	C	T	0.48	-0.106	0.015
rs13099581	3	168226052	T	C	0.14	-0.060	0.022
rs8192675	3	170724883	C	T	0.29	-0.188	0.017
rs6444036	3	184901216	T	G	0.16	0.041	0.021
rs9859406	3	185534482	A	G	0.31	0.167	0.017
rs2041965	3	186648411	T	C	0.34	-0.083	0.016
rs6777684	3	187741842	G	A	0.61	0.134	0.016
rs13094957	3	23457080	C	T	0.20	-0.131	0.019
rs1470560	3	35670150	A	G	0.37	0.037	0.016
rs2624847	3	50174197	T	G	0.74	-0.084	0.017
rs13434089	3	63948566	C	T	0.12	-0.082	0.024
rs9870517	3	64708600	C	A	0.40	-0.096	0.016
rs1374915	3	71668037	C	T	0.42	-0.036	0.016
rs1523766	3	77670448	G	A	0.50	-0.031	0.015
rs978444	3	93981060	T	G	0.55	-0.057	0.015
rs3872707	3	9514016	A	G	0.12	0.049	0.023
rs7659468	4	103895317	G	T	0.49	-0.103	0.015
rs11728350	4	106078097	G	A	0.13	0.110	0.023
rs77141743	4	121774048	A	G	0.16	0.045	0.021
rs730831	4	1240299	G	T	0.04	-0.123	0.041
rs2604918	4	140879929	T	G	0.33	-0.063	0.016
rs2125799	4	156697784	C	T	0.33	0.060	0.016
rs28819812	4	157652753	A	C	0.32	-0.060	0.016
rs4865436	4	1788130	G	C	0.29	0.050	0.018
rs2169033	4	18044357	T	C	0.68	0.081	0.017
rs55691245	4	185716100	A	G	0.14	-0.160	0.022
rs7664347	4	20265535	C	T	0.64	-0.040	0.016
rs10938398	4	45186139	A	G	0.43	0.040	0.016
rs1996617	4	52798624	C	T	0.29	0.101	0.017
rs114447556	4	53207093	T	C	0.08	0.080	0.029
rs10937721	4	6306763	C	G	0.59	0.142	0.016

Downloaded from http://ahajournals.org by on July 19, 2021

rs73222806	4	753840	G	C	0.05	0.098	0.035
rs6835992	4	76496817	G	A	0.69	0.066	0.017
rs993380	4	83584496	G	A	0.67	-0.059	0.016
rs28408270	4	95114572	T	G	0.47	-0.050	0.015
rs1961224	4	95999825	G	A	0.35	-0.065	0.016
rs141146025	5	101966291	A	C	0.02	0.129	0.058
rs75432112	5	102586407	A	G	0.05	0.195	0.036
rs329118	5	133861663	T	C	0.42	0.041	0.016
rs111686785	5	14738965	G	A	0.03	0.182	0.044
rs72734782	5	14789003	G	A	0.21	0.066	0.019
rs12514030	5	14810110	G	T	0.12	-0.103	0.023
rs1650505	5	158029734	A	G	0.21	0.060	0.019
rs4343858	5	176679407	A	G	0.23	-0.042	0.018
rs138373837	5	36219710	T	C	0.02	0.101	0.050
rs62366821	5	44875449	G	A	0.49	-0.055	0.015
rs10067659	5	52084365	C	G	0.79	-0.081	0.019
rs4865796	5	53272664	A	G	0.69	0.049	0.017
rs464605	5	55807370	T	C	0.75	0.080	0.019
rs34341	5	74934009	T	A	0.58	0.073	0.016
rs7732130	5	76435004	A	G	0.68	-0.132	0.016
rs6870983	5	87697533	T	C	0.21	-0.067	0.019
rs34483452	5	87986314	A	C	0.14	0.077	0.023
rs7752666	6	107445266	T	C	0.32	-0.035	0.017
rs80196932	6	117996631	C	T	0.16	-0.064	0.021
rs11759026	6	126792095	G	A	0.23	0.136	0.018
rs2876354	6	137295352	T	C	0.47	-0.083	0.016
rs7742292	6	138864489	C	T	0.40	0.041	0.016
rs2982521	6	139835329	T	A	0.63	-0.110	0.016
rs9390022	6	143056556	C	T	0.38	-0.042	0.016
rs1538247	6	153395344	C	T	0.30	0.093	0.017
rs2179168	6	15477030	A	G	0.80	0.046	0.019
rs501470	6	160770918	G	T	0.47	-0.089	0.015

Downloaded from http://ahajournals.org by on July 19, 2021

rs4709746	6	164133001	T	C	0.13	-0.050	0.023
rs7774074	6	20517130	A	C	0.21	0.039	0.019
rs35261542	6	20675792	A	C	0.26	0.268	0.017
rs3117189	6	32033944	G	A	0.85	0.281	0.021
rs2780215	6	34236973	G	A	0.07	-0.110	0.033
rs7748962	6	43759927	A	G	0.77	0.113	0.018
rs9472139	6	43813711	C	G	0.29	0.065	0.017
rs3798519	6	50788778	C	A	0.18	0.107	0.020
rs9370243	6	53789830	T	G	0.08	0.079	0.028
rs9449295	6	64163807	C	T	0.54	0.036	0.015
rs9379084	6	7231843	A	G	0.12	-0.198	0.025
rs187653072	7	102976385	C	T	0.03	0.134	0.044
rs73184014	7	104516274	G	A	0.22	-0.053	0.019
rs6976111	7	117495667	A	C	0.30	0.074	0.017
rs13237518	7	12269593	A	C	0.41	0.048	0.016
rs3996350	7	130427057	C	G	0.50	-0.086	0.015
rs60251368	7	140522073	G	A	0.06	0.096	0.034
rs4252505	7	142607301	G	A	0.06	0.070	0.031
rs17168486	7	14898282	T	C	0.17	0.162	0.020
rs4725959	7	150534741	G	A	0.22	0.042	0.019
rs10228796	7	15064190	G	C	0.55	0.160	0.015
rs6946660	7	156948648	C	T	0.35	-0.107	0.016
rs11762413	7	2090387	G	C	0.25	-0.085	0.018
rs2188848	7	23884697	G	A	0.20	-0.055	0.019
rs860262	7	28194397	A	C	0.50	-0.158	0.015
rs917195	7	30728452	T	C	0.23	-0.073	0.018
rs730497	7	44223721	A	G	0.18	0.445	0.020
rs73121277	7	50577968	C	T	0.28	0.084	0.017
rs6975279	7	69649683	A	C	0.26	0.101	0.018
rs6956980	7	89803634	C	T	0.53	0.083	0.015
rs7834323	8	10671984	C	T	0.29	-0.074	0.017
rs727582	8	116650468	G	A	0.34	-0.093	0.016

Downloaded from http://ahajournals.org by on July 19, 2021

rs13266634	8	118184783	T	C	0.31	-0.277	0.017
rs12056338	8	12643055	T	G	0.42	0.050	0.016
rs17772814	8	128711742	A	G	0.08	-0.099	0.029
rs1561927	8	129568078	T	C	0.73	-0.048	0.017
rs35753840	8	14148990	C	A	0.39	0.054	0.016
rs13268508	8	145525277	T	C	0.38	0.087	0.016
rs2953845	8	145972950	T	C	0.55	0.042	0.015
rs6558173	8	22492103	T	G	0.35	0.039	0.016
rs2725370	8	30852826	C	T	0.70	-0.049	0.017
rs57735787	8	34438332	G	A	0.25	-0.042	0.018
rs13262861	8	41508577	A	C	0.17	-0.121	0.021
rs7813865	8	57506937	C	T	0.29	0.041	0.017
rs10101067	8	72407374	C	G	0.08	0.092	0.029
rs28792187	8	74568099	G	A	0.07	0.123	0.030
rs1895874	8	95675372	A	G	0.50	0.048	0.015
rs10808671	8	95967372	G	A	0.53	-0.073	0.015
rs60384372	8	9974584	G	A	0.47	-0.056	0.015
rs1567353	9	1033773	G	C	0.31	0.035	0.017
rs10119430	9	111938268	A	G	0.79	-0.054	0.019
rs1431819	9	116943357	G	A	0.70	0.038	0.017
rs10818763	9	125689694	T	C	0.13	-0.108	0.023
rs10739629	9	126093422	T	C	0.51	-0.036	0.015
rs529565	9	136149500	C	T	0.32	0.164	0.017
rs28642213	9	139248082	G	A	0.75	0.169	0.018
rs12380322	9	19074538	G	A	0.39	0.051	0.016
rs10965247	9	22132729	G	A	0.18	-0.302	0.020
rs7018475	9	22137685	G	T	0.26	0.178	0.018
rs11788619	9	22258082	T	A	0.03	-0.134	0.048
rs2150854	9	28411949	T	G	0.33	0.072	0.016
rs4237150	9	4290085	C	G	0.40	0.091	0.016
rs67269808	9	81907986	G	A	0.06	-0.130	0.032
rs2796441	9	84308948	A	G	0.42	-0.096	0.016

Downloaded from http://ahajournals.org by on July 19, 2021

rs7023781	9	96447178	T	C	0.27	0.058	0.017
rs10993072	9	96915002	T	C	0.32	0.083	0.016
rs28496034	9	98278332	G	C	0.33	-0.057	0.016

EAF: effect allele frequency; SE: standard error; SNP: single nucleotide polymorphism.

Downloaded from http://ahajournals.org by on July 19, 2021

Table S5. Genetic proxies for glycemic control by any mechanism, and estimates for their association with glycated hemoglobin (for the outcome of left ventricular ejection fraction).

SNP	Chromosome	Position	Effect allele	Other allele	EAF	Beta	SE
rs2482506	10	104563743	G	C	0.25	-0.053	0.018
rs7090695	10	112801213	C	G	0.80	0.060	0.019
rs11196174	10	114734096	G	A	0.29	0.252	0.017
rs4918790	10	114830254	A	G	0.91	-0.117	0.028
rs4752351	10	121685016	C	T	0.20	0.087	0.019
rs11257655	10	12307894	T	C	0.21	0.219	0.019
rs946859	10	13565429	A	G	0.47	-0.075	0.015
rs3122231	10	44027356	C	T	0.65	0.050	0.016
rs949693	10	70354574	A	G	0.61	-0.050	0.016
rs11592899	10	71333783	A	G	0.34	-0.055	0.016
rs2812535	10	71456857	A	G	0.62	0.069	0.016
rs697239	10	80947438	C	T	0.46	-0.105	0.015
rs11201992	10	88117318	A	C	0.46	-0.038	0.015
rs1111875	10	94462882	T	C	0.41	-0.181	0.016
rs66536955	10	94737667	C	T	0.26	0.044	0.017
rs34041345	10	99174580	G	T	0.26	0.060	0.018
rs529623	11	117693255	C	T	0.52	-0.059	0.015
rs10893830	11	128044159	T	C	0.13	-0.058	0.023
rs10750397	11	128234144	G	A	0.72	-0.040	0.017
rs67232546	11	128398938	T	C	0.21	0.067	0.019
rs757110	11	17418477	A	C	0.64	-0.112	0.016
rs11042987	11	2201059	A	C	0.58	-0.034	0.016
rs2283167	11	2580063	A	G	0.14	-0.055	0.023
rs231362	11	2691471	G	A	0.52	0.120	0.015
rs10767659	11	27686196	T	G	0.67	-0.041	0.016
rs60808706	11	2857233	A	G	0.05	-0.227	0.035
rs2289488	11	2892955	C	G	0.40	0.040	0.016

Downloaded from http://ahajournals.org by on July 19, 2021

rs74673753	11	32623621	T	A	0.06	-0.106	0.033
rs2956092	11	34908780	C	T	0.69	-0.059	0.017
rs3816605	11	47857253	C	T	0.45	-0.080	0.015
rs7483027	11	58128015	C	T	0.38	-0.061	0.016
rs174541	11	61565908	C	T	0.36	-0.098	0.016
rs12789028	11	65326154	A	G	0.20	0.084	0.019
rs11602873	11	72460762	T	A	0.16	-0.187	0.021
rs11236524	11	75464344	C	T	0.09	0.069	0.027
rs2513505	11	76230357	A	C	0.60	0.033	0.016
rs12802861	11	8387806	T	C	0.28	-0.052	0.017
rs10830963	11	92708710	G	C	0.28	0.297	0.017
rs3020069	11	93057087	A	G	0.68	0.093	0.016
rs1426371	12	108629780	A	G	0.26	-0.074	0.018
rs79310463	12	118406696	T	C	0.13	0.104	0.023
rs56348580	12	121432117	C	G	0.31	-0.037	0.017
rs7975763	12	123604053	T	C	0.20	-0.057	0.019
rs2066827	12	12871099	G	T	0.23	0.102	0.018
rs11614914	12	133070294	T	C	0.33	0.078	0.016
rs12828318	12	133766122	G	A	0.18	-0.057	0.020
rs10841886	12	21864377	C	T	0.23	-0.082	0.018
rs1480029	12	26356032	A	G	0.46	0.042	0.015
rs3751239	12	27963676	G	C	0.20	-0.160	0.019
rs7298690	12	4313438	C	T	0.21	0.060	0.019
rs3217893	12	4403876	T	C	0.09	-0.171	0.030
rs2732469	12	48712932	A	T	0.43	-0.258	0.015
rs61937817	12	57212823	G	T	0.11	0.060	0.024
rs11173646	12	61250814	T	A	0.82	-0.046	0.020
rs2257883	12	66216162	A	G	0.13	0.150	0.023
rs12371967	12	66346714	C	T	0.17	-0.043	0.020
rs10879261	12	71520761	G	T	0.41	0.068	0.016
rs11108094	12	95928113	A	C	0.07	0.099	0.030
rs6538805	12	97849120	C	T	0.39	-0.076	0.016

Downloaded from http://ahajournals.org by on July 19, 2021

rs9587811	13	109946882	A	C	0.41	-0.056	0.016
rs314879	13	23309382	T	C	0.79	-0.069	0.019
rs34584161	13	26776999	G	A	0.24	-0.063	0.018
rs380854	13	33574631	A	G	0.58	-0.058	0.016
rs9316500	13	51094114	G	T	0.29	-0.067	0.017
rs7991679	13	58691107	A	T	0.16	-0.081	0.021
rs1215451	13	80715893	A	G	0.29	-0.131	0.017
rs112324411	14	101258584	T	C	0.07	-0.101	0.032
rs2295388	14	101309759	A	G	0.22	-0.073	0.019
rs4906272	14	103376031	T	C	0.16	0.046	0.021
rs12883788	14	33303540	T	C	0.46	0.060	0.015
rs7147483	14	38804675	C	T	0.25	-0.158	0.018
rs723355	14	47304091	A	G	0.50	-0.034	0.015
rs4902002	14	61229411	A	G	0.71	-0.034	0.017
rs242105	14	69459229	C	A	0.28	0.062	0.017
rs7156625	14	79942647	A	G	0.22	0.037	0.019
rs8010382	14	91963722	G	A	0.41	0.046	0.016
rs8043085	15	38828140	T	G	0.23	0.071	0.018
rs11856877	15	40620560	G	A	0.11	0.071	0.024
rs1473781	15	41818917	A	G	0.35	0.067	0.016
rs71472935	15	52565725	C	G	0.11	-0.145	0.025
rs7163757	15	62391608	T	C	0.43	-0.042	0.015
rs7178762	15	63871292	T	C	0.55	-0.057	0.015
rs9479	15	74328576	G	A	0.49	0.052	0.015
rs8033589	15	75596685	A	G	0.76	0.058	0.018
rs12910361	15	77782335	G	A	0.71	0.161	0.017
rs893617	15	90381278	T	C	0.72	-0.136	0.017
rs2290202	15	91512267	T	G	0.13	0.085	0.023
rs9927842	16	15153717	C	T	0.84	-0.056	0.021
rs8056890	16	28897452	A	G	0.36	0.105	0.016
rs8054556	16	29958216	A	G	0.47	0.077	0.015
rs55857387	16	300388	C	T	0.20	-0.142	0.019

Downloaded from http://ahajournals.org by on July 19, 2021

rs8061528	16	3656482	T	C	0.21	0.092	0.019
rs2024449	16	53494617	C	T	0.44	-0.056	0.015
rs1421085	16	53800954	C	T	0.40	0.154	0.016
rs56125990	16	69742387	G	A	0.15	0.065	0.021
rs4788815	16	71634811	T	A	0.66	0.056	0.016
rs72802365	16	75246035	C	G	0.08	-0.163	0.029
rs2966117	16	81599271	T	G	0.48	0.059	0.015
rs11117364	16	88132199	G	A	0.68	0.066	0.017
rs9937296	16	88554480	C	T	0.86	0.069	0.023
rs66461358	16	89535257	C	T	0.15	0.060	0.021
rs12934854	16	950028	A	G	0.17	0.043	0.020
rs925095	17	17344653	T	C	0.39	-0.075	0.016
rs2297508	17	17715317	G	C	0.65	-0.150	0.016
rs9913225	17	27570622	A	G	0.58	-0.075	0.016
rs1109442	17	34862220	C	T	0.47	0.071	0.015
rs3110641	17	36047417	G	A	0.78	0.091	0.019
rs11651755	17	36099840	T	C	0.51	-0.124	0.015
rs3786017	17	3830340	C	T	0.11	0.054	0.025
rs8071043	17	3988451	C	T	0.33	0.066	0.016
rs1905339	17	40582296	C	T	0.34	0.097	0.016
rs35895680	17	47060322	A	C	0.33	-0.089	0.016
rs366577	17	4854480	T	C	0.60	-0.051	0.016
rs57767539	17	62203059	A	G	0.07	0.136	0.031
rs11658220	17	65646092	A	G	0.10	0.100	0.025
rs12603589	17	65825248	C	T	0.19	0.103	0.020
rs7224711	17	76772288	T	C	0.53	-0.069	0.015
rs303760	18	21083738	T	C	0.35	0.052	0.016
rs16965062	18	31581247	T	C	0.43	0.034	0.015
rs7227272	18	36746623	A	G	0.10	-0.062	0.026
rs410150	18	40066006	T	C	0.80	-0.047	0.019
rs17596995	18	53166594	A	G	0.20	-0.049	0.019
rs1517037	18	56878274	T	C	0.19	-0.093	0.020

Downloaded from http://ahajournals.org by on July 19, 2021

rs6567160	18	57829135	C	T	0.23	0.097	0.018
rs74625348	18	60846430	C	G	0.23	-0.044	0.019
rs12963820	18	63426213	A	T	0.27	0.034	0.017
rs7240767	18	7070642	C	T	0.39	0.063	0.016
rs6565922	18	74558999	T	C	0.38	0.078	0.016
rs9384	19	13010643	T	G	0.38	-0.107	0.016
rs10404726	19	18834514	T	C	0.47	-0.035	0.015
rs58542926	19	19379549	T	C	0.08	0.139	0.029
rs924150	19	31829903	C	A	0.39	-0.087	0.016
rs4805881	19	33896432	C	A	0.67	-0.077	0.016
rs429358	19	45411941	C	T	0.16	-0.142	0.021
rs8107527	19	46158417	A	G	0.28	0.105	0.017
rs9304665	19	47602577	A	T	0.77	0.103	0.018
rs2115107	19	7968168	A	G	0.38	0.069	0.016
rs7554251	1	11317932	C	T	0.73	0.036	0.017
rs1127215	1	117532790	T	C	0.42	-0.065	0.016
rs66464442	1	118171801	A	C	0.32	0.121	0.016
rs1493694	1	120526982	T	C	0.11	0.146	0.025
rs115983556	1	149873582	C	A	0.08	-0.153	0.028
rs1194592	1	154324384	G	C	0.44	-0.044	0.015
rs3020781	1	155269776	G	A	0.27	0.086	0.017
rs7546252	1	172368310	G	A	0.56	-0.092	0.015
rs539515	1	177889025	C	A	0.21	0.049	0.019
rs2816177	1	179248952	G	A	0.41	0.049	0.016
rs41304257	1	201849926	G	A	0.28	-0.042	0.017
rs61817176	1	206621028	C	A	0.52	-0.074	0.015
rs10916780	1	20707153	G	A	0.20	-0.045	0.019
rs340874	1	214159256	C	T	0.57	0.166	0.015
rs1337101	1	219726100	T	G	0.32	-0.095	0.016
rs348330	1	229672955	A	G	0.63	-0.119	0.016
rs10925635	1	235573486	C	A	0.64	0.046	0.016
rs17261915	1	26756856	C	T	0.25	0.074	0.018

Downloaded from http://ahajournals.org by on July 19, 2021

rs3753693	1	29060898	T	C	0.41	-0.066	0.016
rs61779284	1	39855177	A	G	0.21	0.130	0.019
rs79090772	1	51209148	C	T	0.09	-0.219	0.027
rs2269247	1	64107284	T	C	0.18	-0.056	0.020
rs11583755	1	6672729	C	A	0.36	0.107	0.016
rs2613499	1	72751552	G	A	0.19	-0.052	0.019
rs10159026	1	96404462	T	C	0.25	-0.062	0.018
rs6137042	20	2100095	A	G	0.20	-0.050	0.019
rs7274134	20	22428284	T	C	0.25	-0.062	0.018
rs6059662	20	32675727	G	A	0.65	0.037	0.016
rs2038457	20	42239145	G	A	0.81	0.041	0.020
rs12625671	20	42994812	C	T	0.11	0.118	0.025
rs6066138	20	45594711	A	G	0.28	-0.135	0.017
rs6021276	20	50155386	C	T	0.64	-0.074	0.016
rs865034	20	51261615	C	T	0.66	0.040	0.016
rs4810145	20	57396495	C	T	0.52	0.068	0.015
rs6011155	20	62450664	C	T	0.37	-0.074	0.016
rs2240716	22	19969696	T	C	0.30	0.074	0.017
rs56392746	22	30451688	A	G	0.09	-0.138	0.026
rs138771	22	35705359	G	A	0.81	-0.055	0.020
rs1801645	22	50356850	T	C	0.74	-0.059	0.018
rs79950062	2	111940612	C	T	0.13	-0.053	0.023
rs9308614	2	121337196	G	A	0.15	-0.090	0.022
rs6716394	2	146350724	A	G	0.54	-0.045	0.015
rs4668483	2	16231732	G	A	0.68	-0.040	0.016
rs10184004	2	165508389	T	C	0.41	-0.115	0.016
rs11680058	2	16574669	A	G	0.87	0.104	0.025
rs13406280	2	166610827	T	C	0.49	-0.047	0.015
rs72917531	2	175238176	A	C	0.19	-0.078	0.020
rs36051007	2	179545859	T	C	0.32	-0.035	0.017
rs67383253	2	181570394	C	T	0.37	-0.035	0.016
rs6712905	2	196952010	C	T	0.26	0.048	0.018

Downloaded from http://ahajournals.org by on July 19, 2021

rs4482463	2	205375909	A	C	0.92	-0.063	0.029
rs34329895	2	208870017	G	A	0.60	-0.063	0.016
rs2943650	2	227105921	T	C	0.65	0.143	0.016
rs13415288	2	228971884	C	T	0.34	0.059	0.016
rs34339006	2	234271522	T	C	0.39	0.092	0.016
rs1260326	2	27730940	C	T	0.61	0.156	0.016
rs921069	2	43206922	G	A	0.58	-0.038	0.016
rs76675804	2	43611883	C	T	0.10	-0.311	0.026
rs10193538	2	58981064	T	G	0.61	0.072	0.016
rs243018	2	60586707	G	C	0.45	0.088	0.016
rs10188334	2	653874	T	C	0.17	-0.087	0.020
rs12185610	2	65661468	C	A	0.41	-0.063	0.016
rs4671799	2	67622243	G	A	0.68	-0.036	0.016
rs4832290	2	86707504	C	T	0.77	-0.053	0.018
rs17036126	3	12287863	T	C	0.13	0.127	0.023
rs11708067	3	123065778	G	A	0.25	-0.262	0.018
rs17036160	3	12329783	T	C	0.12	-0.088	0.024
rs9873519	3	124921457	T	C	0.53	0.097	0.015
rs1225004	3	131626991	C	T	0.28	0.071	0.017
rs667920	3	136069472	T	G	0.77	0.038	0.018
rs6766859	3	138055136	T	C	0.63	-0.091	0.016
rs34573045	3	149196752	G	C	0.43	0.049	0.015
rs7633673	3	152084243	A	G	0.41	-0.086	0.016
rs11706810	3	160159921	C	T	0.48	-0.106	0.015
rs13099581	3	168226052	T	C	0.14	-0.060	0.022
rs8192675	3	170724883	C	T	0.29	-0.188	0.017
rs6444036	3	184901216	T	G	0.16	0.041	0.021
rs9859406	3	185534482	A	G	0.31	0.167	0.017
rs2041965	3	186648411	T	C	0.34	-0.083	0.016
rs6777684	3	187741842	G	A	0.61	0.134	0.016
rs13094957	3	23457080	C	T	0.20	-0.131	0.019
rs1470560	3	35670150	A	G	0.37	0.037	0.016

Downloaded from http://ahajournals.org by on July 19, 2021

rs2624847	3	50174197	T	G	0.74	-0.084	0.017
rs13434089	3	63948566	C	T	0.12	-0.082	0.024
rs9870517	3	64708600	C	A	0.40	-0.096	0.016
rs1374915	3	71668037	C	T	0.42	-0.036	0.016
rs1523766	3	77670448	G	A	0.50	-0.031	0.015
rs978444	3	93981060	T	G	0.55	-0.057	0.015
rs3872707	3	9514016	A	G	0.12	0.049	0.023
rs7659468	4	103895317	G	T	0.49	-0.103	0.015
rs11728350	4	106078097	G	A	0.13	0.110	0.023
rs77141743	4	121774048	A	G	0.16	0.045	0.021
rs2604918	4	140879929	T	G	0.33	-0.063	0.016
rs2125799	4	156697784	C	T	0.33	0.060	0.016
rs28819812	4	157652753	A	C	0.32	-0.060	0.016
rs4865436	4	1788130	G	C	0.29	0.050	0.018
rs2169033	4	18044357	T	C	0.68	0.081	0.017
rs55691245	4	185716100	A	G	0.14	-0.160	0.022
rs7664347	4	20265535	C	T	0.64	-0.040	0.016
rs10938398	4	45186139	A	G	0.43	0.040	0.016
rs1996617	4	52798624	C	T	0.29	0.101	0.017
rs114447556	4	53207093	T	C	0.08	0.080	0.029
rs10937721	4	6306763	C	G	0.59	0.142	0.016
rs75724417	4	757921	T	C	0.05	0.089	0.035
rs6835992	4	76496817	G	A	0.69	0.066	0.017
rs993380	4	83584496	G	A	0.67	-0.059	0.016
rs28408270	4	95114572	T	G	0.47	-0.050	0.015
rs1961224	4	95999825	G	A	0.35	-0.065	0.016
rs116782923	5	102331465	T	A	0.05	0.197	0.034
rs329118	5	133861663	T	C	0.42	0.041	0.016
rs9312873	5	14777799	G	A	0.10	-0.160	0.026
rs1650505	5	158029734	A	G	0.21	0.060	0.019
rs4343858	5	176679407	A	G	0.23	-0.042	0.018
rs62366821	5	44875449	G	A	0.49	-0.055	0.015

Downloaded from http://ahajournals.org by on July 19, 2021

rs10067659	5	52084365	C	G	0.79	-0.081	0.019
rs4865796	5	53272664	A	G	0.69	0.049	0.017
rs464605	5	55807370	T	C	0.75	0.080	0.019
rs34341	5	74934009	T	A	0.58	0.073	0.016
rs7732130	5	76435004	A	G	0.68	-0.132	0.016
rs6870983	5	87697533	T	C	0.21	-0.067	0.019
rs34483452	5	87986314	A	C	0.14	0.077	0.023
rs7752666	6	107445266	T	C	0.32	-0.035	0.017
rs80196932	6	117996631	C	T	0.16	-0.064	0.021
rs11759026	6	126792095	G	A	0.23	0.136	0.018
rs2876354	6	137295352	T	C	0.47	-0.083	0.016
rs7742292	6	138864489	C	T	0.40	0.041	0.016
rs2982521	6	139835329	T	A	0.63	-0.110	0.016
rs9390022	6	143056556	C	T	0.38	-0.042	0.016
rs1538247	6	153395344	C	T	0.30	0.093	0.017
rs2179168	6	15477030	A	G	0.80	0.046	0.019
rs501470	6	160770918	G	T	0.47	-0.089	0.015
rs4709746	6	164133001	T	C	0.13	-0.050	0.023
rs7774074	6	20517130	A	C	0.21	0.039	0.019
rs35261542	6	20675792	A	C	0.26	0.268	0.017
rs3117189	6	32033944	G	A	0.85	0.281	0.021
rs2780215	6	34236973	G	A	0.07	-0.110	0.033
rs7748962	6	43759927	A	G	0.77	0.113	0.018
rs9472139	6	43813711	C	G	0.29	0.065	0.017
rs3798519	6	50788778	C	A	0.18	0.107	0.020
rs9370243	6	53789830	T	G	0.08	0.079	0.028
rs9449295	6	64163807	C	T	0.54	0.036	0.015
rs9379084	6	7231843	A	G	0.12	-0.198	0.025
rs62482399	7	102972707	T	C	0.09	0.087	0.027
rs73184014	7	104516274	G	A	0.22	-0.053	0.019
rs6976111	7	117495667	A	C	0.30	0.074	0.017
rs13237518	7	12269593	A	C	0.41	0.048	0.016

Downloaded from http://ahajournals.org by on July 19, 2021

rs3996350	7	130427057	C	G	0.50	-0.086	0.015
rs60251368	7	140522073	G	A	0.06	0.096	0.034
rs4252505	7	142607301	G	A	0.06	0.070	0.031
rs17168486	7	14898282	T	C	0.17	0.162	0.020
rs4725959	7	150534741	G	A	0.22	0.042	0.019
rs10228796	7	15064190	G	C	0.55	0.160	0.015
rs6946660	7	156948648	C	T	0.35	-0.107	0.016
rs11762413	7	2090387	G	C	0.25	-0.085	0.018
rs2188848	7	23884697	G	A	0.20	-0.055	0.019
rs860262	7	28194397	A	C	0.50	-0.158	0.015
rs917195	7	30728452	T	C	0.23	-0.073	0.018
rs730497	7	44223721	A	G	0.18	0.445	0.020
rs73121277	7	50577968	C	T	0.28	0.084	0.017
rs6975279	7	69649683	A	C	0.26	0.101	0.018
rs6956980	7	89803634	C	T	0.53	0.083	0.015
rs7834323	8	10671984	C	T	0.29	-0.074	0.017
rs727582	8	116650468	G	A	0.34	-0.093	0.016
rs13266634	8	118184783	T	C	0.31	-0.277	0.017
rs12056338	8	12643055	T	G	0.42	0.050	0.016
rs17772814	8	128711742	A	G	0.08	-0.099	0.029
rs1561927	8	129568078	T	C	0.73	-0.048	0.017
rs35753840	8	14148990	C	A	0.39	0.054	0.016
rs13268508	8	145525277	T	C	0.38	0.087	0.016
rs2953845	8	145972950	T	C	0.55	0.042	0.015
rs6558173	8	22492103	T	G	0.35	0.039	0.016
rs2725370	8	30852826	C	T	0.70	-0.049	0.017
rs57735787	8	34438332	G	A	0.25	-0.042	0.018
rs13262861	8	41508577	A	C	0.17	-0.121	0.021
rs7813865	8	57506937	C	T	0.29	0.041	0.017
rs10101067	8	72407374	C	G	0.08	0.092	0.029
rs28792187	8	74568099	G	A	0.07	0.123	0.030
rs1895874	8	95675372	A	G	0.50	0.048	0.015

Downloaded from http://ahajournals.org by on July 19, 2021

rs10808671	8	95967372	G	A	0.53	-0.073	0.015
rs60384372	8	9974584	G	A	0.47	-0.056	0.015
rs1567353	9	1033773	G	C	0.31	0.035	0.017
rs10119430	9	111938268	A	G	0.79	-0.054	0.019
rs1431819	9	116943357	G	A	0.70	0.038	0.017
rs10818763	9	125689694	T	C	0.13	-0.108	0.023
rs10739629	9	126093422	T	C	0.51	-0.036	0.015
rs529565	9	136149500	C	T	0.32	0.164	0.017
rs28642213	9	139248082	G	A	0.75	0.169	0.018
rs12380322	9	19074538	G	A	0.39	0.051	0.016
rs10965247	9	22132729	G	A	0.18	-0.302	0.020
rs7018475	9	22137685	G	T	0.26	0.178	0.018
rs2150854	9	28411949	T	G	0.33	0.072	0.016
rs4237150	9	4290085	C	G	0.40	0.091	0.016
rs67269808	9	81907986	G	A	0.06	-0.130	0.032
rs2796441	9	84308948	A	G	0.42	-0.096	0.016
rs7023781	9	96447178	T	C	0.27	0.058	0.017
rs10993072	9	96915002	T	C	0.32	0.083	0.016
rs28496034	9	98278332	G	C	0.33	-0.057	0.016

EAF: effect allele frequency; SE: standard error; SNP: single nucleotide polymorphism.

Downloaded from http://ahajournals.org by on July 19, 2021

Table S6. **Weighted median sensitivity analyses for the association of genetically proxied glucagon-like peptide receptor (GLP1R) agonism and glycemic control more generally with heart failure (HF; 47,309 cases / 930,014 controls) and left ventricular ejection fraction (LVEF; *n*=16,923).**

Exposure	Outcome	N SNPs	Effect units	Effect	P value
GLP1R	HF	3	Odds ratio	0.77 [0.62, 0.96]	0.02
Glycemia	HF	350	Odds ratio	0.98 [0.96, 1.00]	0.04
GLP1R	LVEF	3	SD change in LVEF	0.18 [-0.07, 0.42]	0.16
Glycemia	LVEF	334	SD change in LVEF	0.00 [-0.02, 0.02]	0.89

SD: standard deviation; SNP: single-nucleotide polymorphism.

Downloaded from http://ahajournals.org by on July 19, 2021

Figure S1. Scatter plot displaying genetic associations of the GLP1R genetic proxies with glycated hemoglobin (mmol/mol, x-axis) and heart failure risk (log-odds, y-axis).



Each point represents a single genetic variant, with vertical and horizontal lines representing standard errors. The slope of the blue diagonal line represents the inverse-variance weighted Mendelian randomization estimate. The *P* value for the Cochran *Q* test for heterogeneity was 0.32. SNP: single-nucleotide polymorphism.

Downloaded from http://ahajournals.org by on July 19, 2021

Figure S2. Scatter plot displaying genetic associations of the GLP1R genetic proxies with type 2 diabetes liability (log-odds, x-axis) and heart failure risk (log-odds, y-axis).



Each point represents a single genetic variant, with vertical and horizontal lines representing standard errors. The slope of the blue diagonal line represents the inverse-variance weighted Mendelian randomization estimate. The *P* value for the Cochran *Q* test for heterogeneity was 0.72. SNP: single-nucleotide polymorphism.

Downloaded from http://ahajournals.org by on July 19, 2021

Figure S3. Scatter plot displaying genetic associations of the GLP1R genetic proxies with glycated hemoglobin (mmol/mol, x-axis) and left ventricular ejection fraction (standard deviation units, y-axis).



Each point represents a single genetic variant, with vertical and horizontal lines representing standard errors. The slope of the blue diagonal line represents the inverse-variance weighted Mendelian randomization estimate. The *P* value for the Cochran *Q* test for heterogeneity was 0.65. SNP: single-nucleotide polymorphism.

Downloaded from http://ahajournals.org by on July 19, 2021

Figure S4. Scatter plot displaying genetic associations of the glycemia genetic proxies with glycated hemoglobin (mmol/mol, x-axis) and heart failure risk (log-odds, y-axis).



Each point represents a single genetic variant, with vertical and horizontal lines representing standard errors. The slope of the blue diagonal line represents the inverse-variance weighted Mendelian randomization estimate. SNP: single-nucleotide polymorphism.

Downloaded from http://ahajournals.org by on July 19, 2021

Figure S5. Scatter plot displaying genetic associations of the glycemia genetic proxies with glycated hemoglobin (mmol/mol, x-axis) and left ventricular ejection fraction (standard deviation units, y-axis).



Each point represents a single genetic variant, with vertical and horizontal lines representing standard errors. The slope of the blue diagonal line represents the inverse-variance weighted Mendelian randomization estimate. SNP: single-nucleotide polymorphism.

Downloaded from http://ahajournals.org by on July 19, 2021